CASI Pharmaceuticals, Inc. · OTC:CASIF

CASI Pharmaceuticals — BIO CEO & Investor Conference 2018

18 slides from CASI Pharmaceuticals's conference presentation, Feb 13, 2018

  1. Slide 1: Corporate Presentation – BIO CEO & Investor Conference

    Slide 1: Corporate Presentation – BIO CEO & Investor Conference

    Corporate Presentation BIO CEO & INVESTOR CONFERENCE New York, NY February 13, 2018

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward- looking statemen

  3. Slide 3: Mission

    Slide 3: Mission

    Mission To Build an Integrated Pharmaceutical Company Serving 1.5 billion People in China with High Quality and Affordable Products while Addressing the U.S. and Global Markets Cost-Effectively Slide 3

  4. Slide 4: Acquisition from Sandoz: 29 ANDA Products and Pipeline

    Slide 4: Acquisition from Sandoz: 29 ANDA Products and Pipeline

    Acquisition from Sandoz 29 ANDA Products and Pipeline 25 FDA Approved, 4 Pending FDA Approval ANDAs Diverse Portfolio Across Attractive Therapeutic Area 12% 35% 19% 15% 8% 11% Hypertension/PVD Metabolic Disorders CNS Anti-infectious Anti-inflammatory/pain Others Slide 4

  5. Slide 5: Historical Opportunity for FDA-Approved ANDAs in China

    Slide 5: Historical Opportunity for FDA-Approved ANDAs in China

    Historical Opportunity for FDA-Approved ANDAs in China Rapidly Establishing A Lead Position in China’s >$100 bn Small Molecule Drug Market Rapid Entry Technology Barriers, Opportunity for Industry Consolidations CFDA’s Bio- CFDA’s BE Waiver on FDA ANDA Equivalence China Products Re-Evaluation of All

  6. Slide 6: Value Proposition

    Slide 6: Value Proposition

    Value Proposition China, America, Synergy, Integration A Unique Competitive Position to Capitalize the Opportunity Cost-Pricing Pressure Government Initiatives Players Exit Generics Industry Consolidation Market Needs Market Needs - Advanced Technology - Fast Growing Market - Science and Innovation

  7. Slide 7: ANDA Development Strategy and Plan

    Slide 7: ANDA Development Strategy and Plan

    ANDA Development Strategy and Plan Self-Development and Partnering with Local Players Year 1 Year 2 In the U.S. FDA File FDA FDA ANDA Re-launch Approved CBE-30 or Modification ANDA products ANDAs PAS Approval in the U.S. Technology FDA/CFDA cGMP Manufacturing In China Transfer to Launch CMO in in Ch

  8. Slide 8: A Platform for Pursuing Additional Product Pipeline Portfolio

    Slide 8: A Platform for Pursuing Additional Product Pipeline Portfolio

    A Platform for Pursuing Additional Product Pipeline Portfolio On the Top List in China with FDA ANDA Products and Pipeline with Opportunity for Rapid Growth Greater China Rights FDA ANDAs Acquired From SPPI ENMD-2076, Global Rights Acquired From Sandoz 25 FDA Approved ANDAs Innovative Drug Candidate

  9. Slide 9: China Market for Zevalin, Marqibo, Evomela

    Slide 9: China Market for Zevalin, Marqibo, Evomela

    China Market for ZEVALIN®, MARQIBO®, EVOMELA™ • Strong IP position, greater China exclusivity, and significant technology barriers • Minimal clinical, regulatory, and financial risks as they are all FDA approved products, already sold in the U.S. • The value of each of the products will increase inc

  10. Slide 10: The Market Potential in China (Evomela)

    Slide 10: The Market Potential in China (Evomela)

    The Market Potential in China • No form of melphalan, branded or generic, is currently available in China – EVOMELA will address an urgent medical need • CASI’s import drug application for EVOMELA was granted priority review by the China FDA, acknowledging the urgent medical need and EVOMELA’s thera

  11. Slide 11: The Market Potential in China (Marqibo)

    Slide 11: The Market Potential in China (Marqibo)

    The Market Potential in China • Proprietary liposomal formulation of vincristine which improves the pharmacokinetics and pharmacodynamics of vincristine* – Higher maximum tolerated dose, superior antitumor activity and delivered higher amounts of active drug to target tissues • Annual incidence of l

  12. Slide 12: The Market Potential in China (Zevalin)

    Slide 12: The Market Potential in China (Zevalin)

    The Market Potential in China • Anti-CD20 antibody coupled to Yttrium-90 ̶ 83% ORR, 39% CR in relapsed or refractory, low-grade or follicular B-cell NHL • Annual incidence of NHL in China is estimated at 83,790 new cases with a mortality of 50,100 cases in 2015*. • ZEVALIN is expected to rapidly pen

  13. Slide 13: Market for Entecavir

    Slide 13: Market for Entecavir

    Market for Entecavir • Hepatitis B virus (HBV) infection remains a severe public health problem worldwide, with 2 billion people currently infected, 360 million having chronic infections and 600,000 deaths annually from either HBV-related liver disease or hepatocellular carcinoma.* • In China, about

  14. Slide 14: China Market for 6 Key ANDA Products

    Slide 14: China Market for 6 Key ANDA Products

    China Market for 6 Key ANDA Products Key Products by 2016 (Estimated) Generic Sales in China Product Indication 2016E Sales (in US$) 1 Entecavir tablet HBV Infection 1,490,000,000 2 Repaglinide tablet Diabetes 225,000,000 3 Bisoprolol Fumarate tablet Hypertension 205,000,000 4 Cilostazol tablet peri

  15. Slide 15: U.S. Market for the Key ANDA Products

    Slide 15: U.S. Market for the Key ANDA Products

    U.S. Market for the 8 Key ANDA Products Key Products by 2016 U.S. Sales* Product Name Indications Sandoz U.S. Sales Overall U..S Generic 2016 (IMS data) Sales 2016 (IMS data) 1 Midodrine Hypotension 19,800,000 56,900,000 2 Triamterene / HCTZ cap Hypertension, diuretic 4,600,000 54,000,000 3 Lisinopr

  16. Slide 16: On Fast Track for Growth and Expansion

    Slide 16: On Fast Track for Growth and Expansion

    On Fast Track for Growth and Expansion Partnership Expansion Commercialization Acquisition Product Pipeline Internal Growth Slide 16

  17. Slide 17: Investment Highlights

    Slide 17: Investment Highlights

    Investment Highlights • Market: Well-positioned to pursue significant and unprecedented market opportunities in China and the U.S. • Model: Compelling business model with important U.S./China synergies and competitive advantage with efficiency and cost-effectiveness for drug development and commerci

  18. Slide 18: NASDAQ: CASI

    Slide 18: NASDAQ: CASI

    NASDAQ: CASI www.casipharmaceuticals.com Slide 18

Source: Internet Archive copy of casipharmaceuticals.com

More decks from CASI Pharmaceuticals, Inc.

All 22 CASI Pharmaceuticals decks